GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fractyl Health Inc (NAS:GUTS) » Definitions » EBITDA Margin %

Fractyl Health (Fractyl Health) EBITDA Margin % : -65,118.18% (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Fractyl Health EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Fractyl Health's EBITDA for the three months ended in Mar. 2024 was $-21.49 Mil. Fractyl Health's Revenue for the three months ended in Mar. 2024 was $0.03 Mil. Therefore, Fractyl Health's EBITDA margin for the quarter that ended in Mar. 2024 was -65,118.18%.


Fractyl Health EBITDA Margin % Historical Data

The historical data trend for Fractyl Health's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fractyl Health EBITDA Margin % Chart

Fractyl Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
- - - - -42,125.00

Fractyl Health Quarterly Data
Dec19 Jun20 Sep20 Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -240,540.00 -16,376.39 -38,302.78 -184,900.00 -65,118.18

Competitive Comparison of Fractyl Health's EBITDA Margin %

For the Biotechnology subindustry, Fractyl Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fractyl Health's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fractyl Health's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Fractyl Health's EBITDA Margin % falls into.



Fractyl Health EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Fractyl Health's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-50.55/0.12
=-42,125.00 %

Fractyl Health's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-21.489/0.033
=-65,118.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fractyl Health  (NAS:GUTS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Fractyl Health EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Fractyl Health's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Fractyl Health (Fractyl Health) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
17 Hartwell Avenue, Lexington, MA, USA, 02421
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity.